An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice

Vaccine

Volumn 20, Issue 3-4, 2001, Pages 421-429

  Niethammer, Andreas G ^a   Primus, F James ^b   Xiang, Rong ^a   Dolman, Carrie S ^a   Ruehlmann, J Michael ^a   Ba, Yi ^a   Gillies, Stephen D ^c   Reisfeld, Ralph A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c Lexigen Pharmaceuticals Corp   (United States)

Author keywords

Antitumor; Carcinoembryonic antigen (CEA); Transgenic mice

Indexed keywords

ANTIBODY KS1 4 INTERLEUKINE 2 FUSION PROTEIN; ANTINEOPLASTIC AGENT; B7 ANTIGEN; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CD2 ANTIGEN; CD28 ANTIGEN; CD48 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; HYBRID PROTEIN; INTERLEUKIN 2 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CELL ACTIVATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; FEEDING; FEMALE; GROWTH INHIBITION; LEWIS CARCINOMA; LUNG METASTASIS; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MALE; MICROBIAL ATTENUATION; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; SKIN TUMOR; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR IMMUNITY;

ADMINISTRATION, ORAL; ANIMALS; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, LEWIS LUNG; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; INTERLEUKIN-12; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; VACCINATION; VACCINES, DNA;

EID: 0035851342     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00362-0     Document Type: Article

References (35)

1. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of 10 original cases, 1893
2. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors
3. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer
4. Interleukin 1 trials in cancer patients: A review of the toxicity, antitumor and hematopoietic effects
5. Tumor antigens recognized by T lymphocytes
6. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection
7. New tumor antigens recognized by T cells
8. Genes coding for tumor antigens recognized by cytolytic T lymphocytes
9. Identification of tumor-regression antigens in melanoma
10. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens
11. Human tumor antigens for cancer vaccine development
12. Design and evaluation of antigen-specific vaccination strategies against cancer
13. Antibody-based immunological therapies
14. Cancer vaccines
15. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy
16. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins
17. T cell memory against colon carcinoma is long-lived in the absence of antigen
18. Melanoma immunotherapy by targeted IL2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction
19. Oral somatic transgene vaccination using attenuated S. typhimurium
20. Regression of established tumors in mice mediated by the oral administration of a recombinant Listeria monocytogenes vaccine
21. Oral delivery of DNA vaccines using attenuated Salmonella typhimurium as carrier
22. Carcinoembryonic antigen gene family: Molecular biology and clinical perspectives
23. Murine monoclonal antibodies against carcinoembryonic antigen: Immunological, pharmacokinetic, and targeting properties in humans
24. Initial clinical experience evaluating Yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer
25. Generation of human CTLs specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine
26. Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy
27. Antibody-IL12 fusion proteins are effective in SCID Mouse models of prostate and colon carcinoma metastases
28. Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA transgenic mice
29. Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma
30. Salmonella vaccine carrier strains: Effective delivery system to trigger anti-tumor immunity by oral route
31. Modulation of host immune responses stimulated by Salmonella vaccine carrier strains by using different promoters to drive the expression of the recombinant antigen
32. Intralymphatic immunization enhances DNA vaccination
33. CD8 T cell clones from young non-obese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells
34. Cells that present both specific ligand and costimulatory activity are the most efficient inducers of clonal expansion of normal CD4 T cells
35. Upstream-downstream: CD28 cosignaling pathways and T cell function